

Study Backs Prophylactic Aortic Root Repair

BY RICHARD M. KIRKNER

FROM AORTIC SYMPOSIUM 2010

NEW YORK — Rupture and tear from an aortic root aneurysm is a major cause of death in Marfan syndrome and Loey-Dietz syndrome, but preventative aortic root repair in these diseases has advanced over the decades to prolong lives and avoid the need for future surgery.

“A prophylactic aortic root replace-

ment in both Marfan syndrome and Loey-Dietz syndrome has very low operative risks and excellent long-term results,” Dr. Duke Cameron of Johns Hopkins in Baltimore said at the symposium, which was sponsored by the American Association for Thoracic Surgery.

Dr. Cameron reported on results of 417 patients with Marfan syndrome who were treated at Johns Hopkins since 1976

and 31 patients with Loey-Dietz syndrome treated over an 8-year period.

In Marfan syndrome, the threshold aortic root diameter indicated for surgery declined over the years to 5 cm, Dr. Cameron said.

“If there’s been a family history of aneurysm or dissection, we’ve lowered the threshold by about 0.5 cm,” he said, adding that in younger patients, enlargement of the aortic root diameter of

more than 1 cm a year is also a reason to operate.

The Hopkins approach for aortic root repair in Marfan syndrome is straightforward, he said: full root replacement with full-thickness, end-to-end anastomosis, mobilization of the three coronary arteries, and root reimplantation. The Hopkins group used a remodeling technique exclusively until 2002, “but became disappointed with annual dilatation and aortic regurgitation seen in some of these patients,” Dr. Cameron said. Now, they perform reimplantation with a Valsalva graft.

The average age of Marfan syndrome patients in the Hopkins’ treatment group was 32; ages ranged from 1.5 to 73 years. Three patients died, including 2 of the 45 patients who had urgent or emergency surgery. None of the patients who had elective operations died within 30 days of the operation. At 20 years after surgery, 75% of patients survived.

Aortic root dissection present at the time of the operation reduced a patient’s late-term survival time by 50%, Dr. Cameron said, “underscoring again the importance of root replacement before dissection occurs.”

A history of mitral valve surgery, seen mostly in younger patients, was also a predictor of late death. The two most prevalent late-term causes of death were dissection or rupture in the distal aortic or ileac arteries and arrhythmia, he said.

However, freedom from thromboembolism in Bentall procedures with mechanical valves surpassed 90% at 25 years, as did freedom from endocarditis, Dr. Cameron said. “This is better than what one would expect to see with an isolated mechanical aortic valve replacement,” he said. “It makes the point that the Bentall procedure is still one of the very best operations we have in cardiac surgery.”

A previous Hopkins’ study showed the Bentall procedure had higher rates of thromboembolism than did valve-sparing aortic root replacement in Marfan syndrome, but valve-sparing surgery had higher rates of reoperation (Ann. Thorac. Surg. 2008;85:2003-10).

Preventative operations in Loey-Dietz syndrome are similar to those for Marfan syndrome, but the threshold aortic root diameter for intervention is lower: 3 cm in children and 4 cm in adults, Dr. Cameron said.

Overall, the 31 patients with Loey-Dietz syndrome who had aortic root repair were half the age of Marfan syndrome patients (15 years on average) with an average sinus diameter of 3.9 cm. All had a valve-sparing procedure, and none died during the operation or at follow-up at an average of 3.6 years, Dr. Cameron said.

“When comparing Loey-Dietz to Marfan syndrome at early to mid-term follow-up, they have very similar operative outcomes,” Dr. Cameron said. ■

Table 2: Bleeding Rates for Non-CABG-Related Bleeding by Weight and Age (TRITON-TIMI 38)

	Major/Minor		Fatal	
	Effient (%)	Clopidogrel (%)	Effient (%)	Clopidogrel (%)
Weight <60kg (N=308 Effient, N=356 clopidogrel)	10.1	6.5	0.0	0.3
Weight ≥60kg (N=6373 Effient, N=6299 clopidogrel)	4.2	3.3	0.3	0.1
Age <75 years (N=5850 Effient, N=5822 clopidogrel)	3.8	2.9	0.2	0.1
Age ≥75 years (N=891 Effient, N=894 clopidogrel)	9.0	6.9	1.0	0.1

Bleeding Related to CABG - In TRITON-TIMI 38, 437 patients who received a thienopyridine underwent CABG during the course of the study. The rate of CABG-related TIMI Major or Minor bleeding was 14.1% for the Effient group and 4.5% in the clopidogrel group (Table 3). The higher risk for bleeding adverse reactions in patients treated with Effient persisted up to 7 days from the most recent dose of study drug.

Table 3: CABG-Related Bleeding (TRITON-TIMI 38)

	Effient (%) (N=213)	Clopidogrel (%) (N=224)
TIMI Major or Minor bleeding	14.1	4.5
TIMI Major bleeding	11.3	3.6
Fatal	0.9	0
Reoperation	3.8	0.5
Transfusion of ≥5 units	6.6	2.2
Intracranial hemorrhage	0	0
TIMI Minor bleeding	2.8	0.9

* Patients may be counted in more than one row.

Bleeding Reported as Adverse Reactions - Hemorrhagic events reported as adverse reactions in TRITON-TIMI 38 were, for Effient and clopidogrel, respectively: epistaxis (6.2%, 3.3%), gastrointestinal hemorrhage (1.5%, 1.0%), hemoptysis (0.6%, 0.5%), subcutaneous hematoma (0.5%, 0.2%), post-procedural hemorrhage (0.5%, 0.2%), retroperitoneal hemorrhage (0.3%, 0.2%), and retinal hemorrhage (0.0%, 0.1%).

Malignancies: During TRITON-TIMI 38, newly diagnosed malignancies were reported in 1.6% and 1.2% of patients treated with prasugrel and clopidogrel, respectively. The sites contributing to the differences were primarily colon and lung. It is unclear if these observations are causally-related or are random occurrences.

Other Adverse Events: In TRITON-TIMI 38, common and other important non-hemorrhagic adverse events were, for Effient and clopidogrel, respectively: severe thrombocytopenia (0.06%, 0.04%), anemia (2.2%, 2.0%), abnormal hepatic function (0.22%, 0.27%), allergic reactions (0.36%, 0.36%), and angioedema (0.06%, 0.04%). Table 4 summarizes the adverse events reported by at least 2.5% of patients.

Table 4: Non-Hemorrhagic Treatment Emergent Adverse Events Reported by at Least 2.5% of Patients in Either Group

	Effient (%) (N=6741)	Clopidogrel (%) (N=6716)
Hypertension	7.5	7.1
Hypercholesterolemia/Hyperlipidemia	7.0	7.4
Headache	5.5	5.3
Back pain	5.0	4.5
Dyspnea	4.9	4.5
Nausea	4.6	4.3
Dizziness	4.1	4.6
Cough	3.9	4.1
Hypotension	3.9	3.8
Fatigue	3.7	4.8
Non-cardiac chest pain	3.1	3.5
Atrial fibrillation	2.9	3.1
Bradycardia	2.9	2.4
Leukopenia (<4 x 10 ⁹ WBC/L)	2.8	3.5
Rash	2.8	2.4
Pyrexia	2.7	2.2
Peripheral edema	2.7	3.0
Pain in extremity	2.6	2.6
Diarrhea	2.3	2.6

7 DRUG INTERACTIONS

7.1 Warfarin: Coadministration of Effient and warfarin increases the risk of bleeding [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

7.2 Non-Steroidal Anti-Inflammatory Drugs: Coadministration of Effient and NSAIDs (used chronically) may increase the risk of bleeding [see Warnings and Precautions (5.1)].

7.3 Other Concomitant Medications: Effient can be administered with drugs that are inducers or inhibitors of cytochrome P450 enzymes [see Clinical Pharmacology (12.3)].

Effient can be administered with aspirin (75 mg to 325 mg per day), heparin, GPIIb/IIIa inhibitors, statins, digoxin, and drugs that elevate gastric pH, including proton pump inhibitors and H₂ blockers [see Clinical Pharmacology (12.3)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy: Pregnancy Category B - There are no adequate and well controlled studies of Effient use in pregnant women. Reproductive and developmental toxicology studies in rats and rabbits at doses of up to 30 times the recommended therapeutic exposures in humans (based on plasma exposures to the major circulating human metabolite) revealed no evidence of fetal harm; however, animal studies are not always predictive of a human response. Effient should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.

In embryo fetal developmental toxicology studies, pregnant rats and rabbits received prasugrel at maternally toxic oral doses equivalent to more than 40 times the human exposure. A slight decrease in pup body weight was observed; but, there were no structural malformations in either species. In prenatal and postnatal rat studies, maternal treatment with prasugrel had no effect on the behavioral or reproductive development of the offspring at doses greater than 150 times the human exposure [see Nonclinical Toxicology (13.1)].

8.3 Nursing Mothers: It is not known whether Effient is excreted in human milk; however, metabolites of Effient were found in rat milk. Because many drugs are excreted in human milk, prasugrel should be used during nursing only if the potential benefit to the mother justifies the potential risk to the nursing infant.

8.4 Pediatric Use: Safety and effectiveness in pediatric patients have not been established [see Clinical Pharmacology (12.3)].

8.5 Geriatric Use: In TRITON-TIMI 38, 38.5% of patients were ≥65 years of age and 13.2% were ≥75 years of age. The risk of bleeding increased with advancing age in both treatment groups, although the relative risk of bleeding (Effient compared with clopidogrel) was similar across age groups.

Patients ≥75 years of age who received Effient had an increased risk of fatal bleeding events (1.0%) compared to patients who received clopidogrel (0.1%). In patients ≥75 years of age, symptomatic intracranial hemorrhage occurred in 7 patients (0.8%) who received Effient and in 3 patients (0.3%) who received clopidogrel. Because of the risk of bleeding, and because effectiveness is uncertain in patients ≥75 years of age [see Clinical Studies (14)], use of Effient is generally not recommended in these patients, except in high-risk situations (diabetes and past history of myocardial infarction) where its effect appears to be greater and its use may be considered [see Warnings and Precautions (5.1), Clinical Pharmacology (12.3), and Clinical Studies (14)].

8.6 Low Body Weight: In TRITON-TIMI 38, 4.6% of patients treated with Effient had body weight <60 kg. Individuals with body weight <60 kg had an increased risk of bleeding and an increased exposure to the active metabolite of prasugrel [see Dosage and Administration (2), Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)]. Consider lowering the maintenance dose to 5 mg in patients <60 kg. The effectiveness and safety of the 5 mg dose have not been prospectively studied.

8.7 Renal Impairment: No dosage adjustment is necessary for patients with renal impairment. There is limited experience in patients with end-stage renal disease [see Clinical Pharmacology (12.3)].

8.8 Hepatic Impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment (Child-Pugh Class A and B). The pharmacokinetics and pharmacodynamics of prasugrel in patients with severe hepatic disease have not been studied, but such patients are generally at higher risk of bleeding [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

8.9 Metabolic Status: In healthy subjects, patients with stable atherosclerosis, and patients with ACS receiving prasugrel, there was no relevant effect of genetic variation in CYP2B6, CYP2C9, CYP2C19, or CYP3A5 on the pharmacokinetics of prasugrel’s active metabolite or its inhibition of platelet aggregation.

10 OVERDOSAGE

10.1 Signs and Symptoms: Platelet inhibition by prasugrel is rapid and irreversible, lasting for the life of the platelet, and is unlikely to be increased in the event of an overdose. In rats, lethality was observed after administration of 2000 mg/kg. Symptoms of acute toxicity in dogs included emesis, increased serum alkaline phosphatase, and hepatocellular atrophy. Symptoms of acute toxicity in rats included mydriasis, irregular respiration, decreased locomotor activity, ptosis, staggering gait, and lacrimation.

10.2 Recommendations about Specific Treatment: Platelet transfusion may restore clotting ability. The prasugrel active metabolite is not likely to be removed by dialysis.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility: **Carcinogenesis** - No compound-related tumors were observed in a 2-year rat study with prasugrel at oral doses up to 100 mg/kg/day (>100 times the recommended therapeutic exposures in humans (based on plasma exposures to the major circulating human metabolite). There was an increased incidence of tumors (hepatocellular adenomas) in mice exposed for 2 years to high doses (>250 times the human metabolite exposure).

Mutagenesis - Prasugrel was not genotoxic in two *in vitro* tests (Ames bacterial gene mutation test, clastogenicity assay in Chinese hamster fibroblasts) and in one *in vivo* test (micronucleus test by intraperitoneal route in mice).

Impairment of Fertility - Prasugrel had no effect on fertility of male and female rats at oral doses up to 300 mg/kg/day (80 times the human major metabolite exposure at daily dose of 10 mg prasugrel).

17 PATIENT COUNSELING INFORMATION

See Medication Guide

17.1 Benefits and Risks

- Summarize the effectiveness features and potential side effects of Effient.
- Tell patients to take Effient exactly as prescribed.
- Remind patients not to discontinue Effient without first discussing it with the physician who prescribed Effient.
- Recommend that patients read the Medication Guide.

17.2 Bleeding:

- Inform patients that they:
- will bruise and bleed more easily.
 - will take longer than usual to stop bleeding.
 - should report any unanticipated, prolonged, or excessive bleeding, or blood in their stool or urine.

17.3 Other Signs and Symptoms Requiring Medical Attention

- Inform patients that TTP is a rare but serious condition that has been reported with medications in this class of drugs.
- Instruct patients to get prompt medical attention if they experience any of the following symptoms that cannot otherwise be explained: fever, weakness, extreme skin paleness, purple skin patches, yellowing of the skin or eyes, or neurological changes.

17.4 Invasive Procedures:

- Instruct patients to:
- inform physicians and dentists that they are taking Effient before any invasive procedure is scheduled.
 - tell the doctor performing the invasive procedure to talk to the prescribing health care professional before stopping Effient.

17.5 Concomitant Medications: Ask patients to list all prescription medications, over-the-counter medications, or dietary supplements they are taking or plan to take so the physician knows about other treatments that may affect bleeding risk (e.g., warfarin and NSAIDs).

Literature Issued: July 10, 2009

Manufactured by Eli Lilly and Company, Indianapolis, IN, 46285

Marketed by Daiichi Sankyo, Inc. and Eli Lilly and Company

Copyright © 2009, Daiichi Sankyo, Inc. and Eli Lilly and Company. All rights reserved. PG62281

PV 7310 AMP
PRINTED IN USA

References: 1. Effient® (prasugrel) prescribing information. Daiichi Sankyo, Inc. and Eli Lilly and Company. 2. Data on file: #EFF20100129h: DSI/Lilly. 3. Data on file: #EFF20091204b: DSI/Lilly. 4. Data on file: #EFF20100129f: DSI/Lilly.



®Effient and the Effient logo are registered trademarks of Eli Lilly and Company. Plavix® is a registered trademark of sanofi-aventis Corp.

Copyright © 2010 Daiichi Sankyo, Inc. and Lilly USA, LLC. All Rights Reserved. PG53128. Printed in USA. June 2010.

Disclosures: Dr. Cameron had no disclosures relevant to his presentation.